Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2008.

Total revenues in the first quarter of 2008 were $2.6 million, compared to $4.9 million in the first quarter of 2007, and included $2.0 million in revenue under Arena's contract manufacturing agreement with Siegfried Ltd and $0.6 million in patent reimbursements from Arena's collaborations with Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. Arena reported a net loss allocable to common stockholders in the first quarter of 2008 of $55.0 million, or $0.75 per share, compared to a net loss allocable to common stockholders in the first quarter of 2007 of $32.4 million, or $0.53 per share.

"In the first quarter of 2008, we purchased certain pharmaceutical manufacturing assets from Siegfried and secured Siegfried as a supplier of lorcaserin for our planned NDA submission in 2009 and for the potential partnering and commercialization of the drug candidate. Additionally, lorcaserin passed the month-12 ESMB review of echocardiographic data, APD125, our insomnia drug candidate, entered a Phase 2b trial and APD791, our drug candidate for arterial thrombosis, entered a Phase 1b trial," stated Jack Lief, Arena's President and Chief Executive Officer. "This is a productive start to the year, and we look forward to the results from our ongoing clinical trials and advancing our pipeline of innovative therapeutics."

Research and development expenses totaled $47.6 million in the first quarter of 2008, compared to $35.8 million in the first quarter of 2007. This increase in research and development expenses is primarily attributable to increased clinical development c
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grange™ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... 29, 2014 Quorum Review IRB, ... been awarded accreditation by the International Association ... Lean Six Sigma Deployment Program. The citation recognizes ... performance. , Quorum’s Lean Six Sigma program was ... Program designation. The designation is a public statement ...
(Date:7/29/2014)... 29, 2014 The first product launch ... generation approach to robotics. What sets Droidles completely apart ... technology that allows them to communicate, share code with ... the internet. , “The invention is the system,” said ... Droidles a life of their own, both physically and ...
(Date:7/29/2014)... Jason Wendel – recipient of a Regional Top Doctor Award ... Plastic Surgeon Specialists for Nashville, TN – has released a ... a Hydration Booster, Retexturing Night Crème, and Anti-aging C Complex, ... more radiant appearance while protecting them from the sun’s harmful ... at Dr. J. J. Wendel Plastic Surgery, we have developed ...
Breaking Biology Technology:Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2Dr. J. J. Wendel Launches New Line of Skin Care Products 2
... have developed the first functional oxide thin films that ... to an array of new high-power devices and smart ... been able to produce positively charged (p-type) conduction and ... launching a new era in oxide electronics. To ...
... California, San Diego electrical engineers are building a forest of ... without using fossil fuels and harvest it for hydrogen fuel ... said nanowires, which are made from abundant natural materials like ... deliver hydrogen fuel on a mass scale. "This ...
... Eye Research Institute, a subsidiary of Mass. Eye and Ear ... first time that a bacterial pathogen can literally mow down ... and infect a part of the body. Their landmark study, ... , describes how they discovered that an "epidemic" strain ...
Cached Biology Technology:Functional oxide thin films create new field of oxide electronics 2Nanotrees harvest the sun's energy to turn water into hydrogen fuel 2Scientists Discover How a Bacterial Pathogen Breaks Down Barriers to Enter and Infect Cells 2Scientists Discover How a Bacterial Pathogen Breaks Down Barriers to Enter and Infect Cells 3
(Date:7/29/2014)... San Francisco is the first to show that while ... cellular aging, these negative effects may be reduced by ... , "The study participants who exercised, slept well and ... who didn,t maintain healthy lifestyles, even when they had ... PhD, assistant professor in the department of psychiatry at ...
(Date:7/28/2014)... people in the United States have a circulatory problem ... be painful and may even require surgery in serious ... wasting and, in turn, limb amputation. , At The ... Medical School, scientists tested a non-surgical preventative treatment in ... associated with increased blood circulation. Their proof-of-concept study ...
(Date:7/28/2014)... genome of Solanum pennellii , a wild relative ... international group of researchers including the labs headed by ... Davis Department of Plant Biology. The new genome information ... The work, published July 27 in the journal ... colleagues at Aachen University in Germany. The UC Davis ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... CHAPEL HILL, N.C. -- There has been controversy about ... about whether enough time has elapsed for life to have ... the University of North Carolina at Chapel Hill investigating the ... the time required for evolution on a warm earth is ...
... OH, December 2, 2010 -- Managing diabetes in a child ... Buying essential medical supplies, such as needles and testing strips, ... new study soon to be published in The Journal ... the financial burden of diabetes management increases a child,s risk ...
... December 1, 2010 The versatile organism Lactococcus ... into cheese, may also be valuable in the understanding ... biofuels. New research from Concordia University, published ... the bacterium can be engineered to transform plant material ...
Cached Biology News:Heat helped hasten life's beginnings 2New study calls for greater awareness of food supply for children with diabetes 2
... cells-directed transfection reagent : jetPEI-RGD ... which allows targeted efficient transfection ... cells. Integrins are adhesion molecules ... adhesion processes. Many integrins, including ...
... used on Macintosh operating systems to ... DNA sequence up to 3,200 bases, ... primers and GC clamps for mutation ... (DGGE), constant denaturing gel electrophoresis (CDGE), ...
... The Mini-Sub cell GT cell and PowerPac basic ... electrophoresis of nucleic acids in agarose gels. The ... lid with cables and electrodes, a 7 x ... two casting gates, and two 1.5 mm fixed-height ...
... top-of-the-line PowerPac 3000 power supply is ... ideal for isoelectric focusing, DNA sequencing, ... electrophoresis, western blotting, and submerged gel ... of powre, the PowerPac 3000 power ...
Biology Products: